|
AstraZeneca PLC on Tuesday said its Covid vaccine Vaxzevria won full marketing authorisation in the EU.
"As there continues to be sufficient evidence of safety and efficacy confirming the benefits of Vaxzevria, the European Medicines Agency has now granted a full marketing authorisation. This decision follows positive recommendation for a full MA by the Committee for Medicinal Products for Human Use of the EMA," the Cambridge-based pharmaceutical company said.
In May, Astra announced that Vaxzevria received marketing authorisation in the EU as third-dose booster.
The full marketing authorisation the vaccine has now covers the use of Vaxzevria as primary vaccination in a heterologous setting, which means injection of the Vaxzevria jab as well as one or several approved mRNA Covid jabs, and in a homologous setting, where all Covid jabs are the same vaccine.
AstraZeneca shares were 0.9% higher at 10,348.00 pence each in London on Tuesday morning.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
